Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Myfenax vs CellCept in Renal Transplant
NCT00991510Phase 4Terminated
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Aug 2009
- Primary completion
- Oct 2010
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial of mycophenolate mofetil in kidney transplant rejection (2 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Area Under the Plasma Concentration-time Curve (AUC(0-6h)) of Mycophenolate Mofetil at Day 28, Area Under the Plasma Concentration-time Curve (AUC(0-tau)) of Mycophenolate Mofetil at Day 28 and 1 more. Started Aug 2009; status: terminated.
02
Drugs
mycophenolate mofetil
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00991510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00991510.